4 views

N-Acetyl Selank

Acetylated Selank with improved bioavailability for anxiety relief

Overview

N-Acetyl Selank is an acetylated variant of Selank designed for enhanced stability and improved blood-brain barrier penetration. The acetyl group modification protects the peptide from enzymatic degradation and may increase its bioavailability and potency compared to standard Selank. Like its parent compound, N-Acetyl Selank is based on the endogenous immunomodulatory peptide tuftsin and demonstrates anxiolytic and nootropic properties. Research indicates the modification may provide stronger effects on brain-derived neurotrophic factor (BDNF) expression and more pronounced cognitive enhancement. The peptide modulates neurotransmitter systems including serotonin and dopamine without sedation or dependence. Studies suggest improved memory consolidation, reduced anxiety, and enhanced focus. N-Acetyl Selank is typically administered intranasally for optimal brain delivery. The enhanced version may require lower doses to achieve similar effects as standard Selank. While research supports its cognitive and anxiolytic properties, comprehensive clinical trials comparing the acetylated and non-acetylated forms are limited.

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

NA-SelankN-Acetyl Selank AmidateAcetylated SelankSelank derivative

CAS2703745-90-6

PubChem133082488

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Anxiety disordersCognitive enhancementNootropic researchPeptide stability / delivery

Available Evidence

Human

The parent compound Selank has clinical data from Russia: a study of 62 patients with generalized anxiety disorder and neurasthenia reported anxiolytic effects similar to medazepam with additional antiasthenic/psychostimulant effects. No dedicated published clinical trials of the N-acetylated variant itself were found.

Animal

Selank and its analogs have been studied in rodent models for anxiolytic and cognitive effects; the N-acetyl modification is claimed to improve stability and brain penetration, but published side-by-side animal data for the acetylated form are limited.

In Vitro

The acetylation of the N-terminus is a common peptide-stabilization strategy intended to resist aminopeptidase degradation; detailed in-vitro comparative data specific to N-acetyl-selank are scarce in the indexed literature.

Uncertain

Claims that N-acetyl-selank outperforms Selank on bioavailability, BDNF expression, or potency are based largely on vendor/derivative reasoning rather than published comparative clinical studies. No regulatory approvals exist.

Key Studies & Findings

1 studies

Clinical2008

In 62 patients with generalized anxiety disorder and neurasthenia, Selank (30 patients) produced anxiolytic effects similar to medazepam (32 patients) with additional antiasthenic and psychostimulant effects.

Clinical study (Zh Nevrol Psikhiatr Im S S Korsakova, Russian-language)

Benefits & Effects

4 documented

Enhanced anxiolytic effects

anecdotalCognitive

View Source

Improved stability vs Selank

anecdotalPharmacokinetics

View Source

Memory protection

anecdotalCognitive

View Source

BDNF regulation

anecdotalCognitive

View Source

Side Effects & Safety

2 reported

Well-tolerated

MildRare Reversible

View Source

Nasal irritation

MildRare Reversible

Onset: immediate

View Source

Limitations & Open Questions

The human evidence base belongs to the parent peptide Selank (Russian studies, mostly small and non-placebo-controlled). There are no indexed clinical trials, pharmacokinetic studies, or comparative efficacy data specific to N-acetyl-selank; the acetylated form is essentially an unstudied derivative sold for research use.

Pharmacology

Selank is a tuftsin-derived heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro). N-acetyl-selank is the N-terminally acetylated version, intended to resist enzymatic degradation and improve stability/penetration; no published half-life or pharmacokinetic data for the acetylated form were found in indexed sources. Selank has been administered intranasally and SC in research/clinical use.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

200-400 mcg Daily

Route: Intranasal

Half-life: ~10 minutes

Frequently Asked Questions

What is the difference between Selank and N-acetyl-selank?

N-acetyl-selank adds an acetyl group to the N-terminus of Selank, a stability modification intended to reduce enzymatic degradation; it is otherwise the same peptide sequence.

Has N-acetyl-selank been studied in clinical trials?

No dedicated clinical trials of the N-acetyl form were found. Clinical data exist for the parent compound Selank from Russian studies in anxiety disorders.